Close Menu

NEW YORK – Biodesix said today that it has signed an agreement with Thermo Fisher Scientific to develop and seek US Food and Drug Administration approval for a sequencing-based lung cancer liquid biopsy diagnostic test.

Under the agreement, Biodesix will generate analytical and clinical data using Thermo Fisher's Ion Torrent Oncomine Pan-Cancer Cell-Free Assay to apply for premarket approval (PMA) from the FDA. The initiative will focus on patients with advanced non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.